Alexandria Venture Investments has taken part in the final close of the series B round, which will fund development of the company's cell therapy platform.

US-based cell therapy developer Immusoft has completed a $20m series B round that included the strategic investment division of life sciences real estate investment trust Alexandria Real Estate Equities. Alexandria Venture Investments was joined in the round by Breakout Ventures, a vehicle for fellowship Thiel Foundation’s Breakout Labs, as well as RBV Capital, Defta Partners…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.